Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer

15 May 2014

Abstract excerpt

The involvement of Axl kinase in non-small cell lung cancer's (NSCLC) acquired resistance to tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has been identified recently, but the mechanism by which Axl contributes to TKI resistance is largely unknown. MicroRNAs (miRNAs) repress gene expression and their critical role in tumorigenesis has been implicated. To investigate the role of miRNAs in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to MicroRNA in disease regulation
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24832599
DOI: 10.1038/cddis.2014.186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancerPMID 24832599Read ↗

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCSemantic proximity Read ↗

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.Semantic proximity Read ↗

The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.Semantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.Semantic proximity Read ↗

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read ↗

MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung CancerSemantic proximity Read ↗

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read ↗

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell linesSemantic proximity Read ↗

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsSemantic proximity Read ↗

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Semantic proximity Read ↗

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.